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Introduction P reventing the transmission of infectious diseases through blood transfusion in developing countries is difficult given that the resources required are not always available, even when policies and strategies are in place. The strategies that have been used to reduce Transfusion Transmitted Infection (TTI) includes improving donors selection, testing the donated blood for specific antibodies for infectious agents, reducing exposure to allogenic blood by use of autologous transfusion and changing transfusion guidelines to use blood more conservatively. These strategies have been extremely effective [1, 2] , but transmission of diseases still occurs [3] , primarily because of the inability of the test to detect the disease in the pre-seroconversion or "window" phase of their infection, immunologically variant viruses, nonseroconverting chronic or immuno -silent carriers and laboratory testing errors [4 ] . TTI is still a major concern to patients, physicians and policy makers who wish to see a risk-free blood supply.
This study presents data on the prevalence rate of . All the reactive samples were repeat tested before labelling them seropositive. The donated blood was discarded whenever the pilot donor sample was found positive for any TTI.
Materials and Method
The statistical analysis was done using Chi square test for trends in proportions when proportions are very small (close to zero). In all the markers tested, there is increased positivity rate amongst the replacement donors as compared to the voluntary donations.
Discussion
The risk of TTI has declined dramatically in highincome nations over the past two decades, primarily because of extraordinary success in preventing HIV and other established transfusion-transmitted viruses from entering the blood supply [5] . But the same may not hold good for the developing countries. The National Recent studies in the west, have shown that the estimated risk of transfusion-transmitted HIV, HCV and to a lesser extent HBV infection via blood products is very low [6] [7] [8] . Glynn et al [9] , reported that since the introduction of nucleic acid amplification testing (NAT) in the screening procedure of blood donations, the estimated risk of HCV and HIV infections has decreased two-fold for HIV and by a factor of almost 10 for HCV. In this study, the maximum prevalence rate of HIV amongst voluntary donors is 0.97% and 2.22% in replacement donors. This prevalence rate ranges from 0.55% to 3.87%, as reported in other studies in India [10] [11] [12] . In 2002 the number of voluntary donors were 73.5% and the HIV positivity was 0.49% as compared to 55.2% and 0.22% respectively in 2004. The incidence of HCV infection amongst the replacement donors is gradually increasing from 0.43% to 0.65%, but the incidence in our study is lower, as compared to other studies (0.12% -4%) [13, 14] . Our findings of HBsAg seropositivity of 1.22% and 2.59% amongst voluntary and replacement donors respectively is comparable to other reported Indian studies (1.2% -3.5%) [15] . The seropositivity of HBsAg amongst replacement donors has remained static, but it has decreased from 1.67% to 0.77% amongst the voluntary donors, during the last five year period. It may be due to screening by third generation kits with higher sensitivity and specificity. Currently, testing for syphilis by VDRL method may not be sensitive, but it is essential to exclude high-risk donors.
The major concern in transfusion services today is increased seropositivity amongst replacement donors for HCV, HIV and HBsAg. This could be decreased by introduction of NAT in minipools for HCV and HIV as in western countries and introduction of anti-hepatitis B core antigen (HBcAg) IgM for HBV infection. This will decrease the 'window-period' and hence decrease the incidence of TTI. But, the cost-effectiveness of NAT is poor even in USA. Overall, NAT would cost between 4.7 million US dollars and 11.2 million US dollars per quality-adjusted life-year saved for HIV, HCV and HBV in whole-blood donations [16] .
To conclude, with the implementation of strict donor criteria and use of sensitive laboratory screening tests, it may be possible to reduce the incidence of TTI in the Indian scenario.
